Catapult Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Catapult Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$433K	Sell	55,000 -20,000	-27%	-$185K	0.16%	129
2015 Q2	$680K	Sell	75,000 -35,000	-32%	-$353K	0.1%	192
2015 Q1	$1.43M	Hold	110,000	–	–	0.17%	152
2014 Q4	$1.5M	Buy	110,000 +26,627	+32%	+$298K	0.38%	86
2014 Q3	$748K	Buy	+83,373	New	+$897K	0.08%	160

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Catapult Capital Management's GNMK Position: Q3 2015 in Review

Catapult Capital Management reduced its GenMark Diagnostics, Inc (GNMK) stake by 27% in Q3 2015, selling an estimated $185K and leaving 55,000 shares worth $433K. The position accounts for 0.16% of the portfolio, ranked #129.

Catapult Capital Management first reported a position in GNMK in Q3 2014 and has held it in 5 quarters since. The position peaked at $1.5M in Q4 2014. 88 funds tracked by Wall St. Rank hold GNMK as of Q3 2015.

Catapult Capital Management held 55,000 shares of GenMark Diagnostics, Inc worth $433K as of Q3 2015.
Catapult Capital Management sold 20,000 GenMark Diagnostics, Inc shares in Q3 2015, an estimated $185K.
GenMark Diagnostics, Inc made up 0.16% of Catapult Capital Management's portfolio in Q3 2015, its #129 holding.
Catapult Capital Management first reported a position in GenMark Diagnostics, Inc in Q3 2014 and has held it in 5 quarters since.
Catapult Capital Management's GenMark Diagnostics, Inc position peaked at $1.5M in Q4 2014.
88 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.